This photo provided by Revolution Medicines on Wednesday, Aug. 26, 2026 shows packaging for the new pancreatic cancer drug, daraxonrasib, under the brand name Rasonque. (Revolution Medicines via AP)
\n\nA sign for the U.S. Food and Drug Administration is displayed outside their offices in Silver Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File)
\n\nWASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer.
\n\nFDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, which blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases. It’s an approach that previously eluded drugmakers for decades.
\n\nThe daily pills will be sold by Revolution Medicines under the brand name Rasonque. A one-month supply would cost approximately $39,800, the company announced.
\n\nPatients taking the drug nearly doubled their survival time, with fewer severe side effects, in a study that randomly assigned them to receive the experimental treatment or more chemotherapy. The company-funded study enrolled 500 patients whose metastatic, or spreading, cancer had quit responding to prior treatment.
\n\nPatients getting the new…
Original source: https://apnews.com/business
